Market Overview

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Share:

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”

Corcept Therapeutics closed on Friday at $4.08.

Latest Ratings for CORT

DateFirmActionFromTo
Feb 2019DowngradesOverweightNeutral
Dec 2018UpgradesNeutralOverweight
Aug 2018Initiates Coverage OnNeutral

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (CORT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ANABMaintains93.0
SHOPDowngrades300.0
AMTDMaintains56.0
HCAMaintains181.0
LOWMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Morning Market Losers

UPDATE: Stifel Reiterates on Teledyne Technologies Following Analyst/Investor Day